BMS strikes back against Merck in EU oesophageal cancer marketMerck & Co’s Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment Share XBMS strikes back against Merck in EU oesophageal cancer markethttps://pharmaphorum.com/news/bms-strikes-back-against-merck-in-eu-oesophageal-cancer-market/
Keytruda backed by NICE for late-stage oesophageal cancerMSD’s Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making Share XKeytruda backed by NICE for late-stage oesophageal cancerhttps://pharmaphorum.com/news/keytruda-backed-by-nice-for-late-stage-oesophageal-cancer/
First FDA filing for Novartis’ latecomer PD-1 drug tislelizumabNovartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier Share XFirst FDA filing for Novartis’ latecomer PD-1 drug tislelizumabhttps://pharmaphorum.com/news/first-fda-filing-for-novartis-latecomer-pd-1-drug-tislelizumab/
BMS claims first EU okay for adjuvant oesophageal cancer immunotherapyBristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy Share XBMS claims first EU okay for adjuvant oesophageal cancer immunotherapyhttps://pharmaphorum.com/news/bms-claims-eu-okay-for-opdivo-in-adjuvant-oesophageal-cancer/
Keytruda beats Opdivo to first-line oesophageal cancer OK in EuropeMerck & Co’s Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer Share XKeytruda beats Opdivo to first-line oesophageal cancer OK in Europehttps://pharmaphorum.com/news/keytruda-beats-opdivo-to-first-line-oesophageal-cancer-ok-in-europe/
Keytruda cuts risk of death by 31% in esophageal cancer trialMSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma Share XKeytruda cuts risk of death by 31% in esophageal cancer trialhttps://pharmaphorum.com/news/keytruda-cuts-risk-of-death-by-31-in-esophageal-cancer-trial/
